Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | PKM | P14618 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | NQO2 | P16083 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | GFER | P55789 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2136849 | 0.79 | IDO1 (0.55) | MEN1KMT2AMAPTKDM4EGAA | |
| SCHEMBL84829 | 0.79 | CYP3A4 (0.57) | MEN1KMT2AMAPTKDM4EGAA | |
| SCHEMBL2141157 | 0.77 | DCPS (0.49) | MEN1KMT2AMAPTKDM4EGAA | |
| SCHEMBL2140697 | 0.77 | MEN1 (0.44) | MEN1KMT2AMAPTKDM4EGAA | |
| SCHEMBL2136353 | 0.77 | MAPT (1.00) | MEN1KMT2AMAPTKDM4EGAA | |
| SCHEMBL8040045 | 0.77 | NQO2 (0.47) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL8052248 | 0.76 | NQO2 (0.47) | MEN1KMT2AMAPTKDM4EGAA | |
| SCHEMBL25321763 | 0.75 | MAPT (0.66) | MEN1KMT2AMAPTKDM4EGAA | |
| SCHEMBL2749006 | 0.75 | ALDH1A1 (0.58) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL2748734 | 0.75 | NQO2 (0.46) | MEN1KMT2AMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2018013774-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
| US-8242278-B2 | Process for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20120101278-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | HAGIYA KOJI (JP) | 2012-04-26 | — | — | US | disclosed |
| EP-1473286-B1 | PROCESS FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2009-11-04 | — | — | EP | disclosed |
| US-20090216017-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | HAGIYA KOJI | 2009-08-27 | — | — | US | disclosed |
| US-7554000-B2 | Process for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20050096471-A1 | Process for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-05-05 | — | — | US | disclosed |
| EP-1473286-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2004-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101278-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | PPOX, CAT, TYR | MEN1 3325/4885KMT2A 575/4885MAPT 3403/4885 |
| US-20090216017-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | PPOX, CAT, TYR | MEN1 3325/4885KMT2A 575/4885MAPT 3403/4885 |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, PF4 | MEN1 1767/4885KMT2A 2420/4885MAPT 1432/4885 |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, F12 | MEN1 1492/4885KMT2A 2390/4885MAPT 1155/4885 |
| US-20050096471-A1 | Process for producing biaryl compound | PPOX, CAT, TYR | MEN1 3325/4885KMT2A 575/4885MAPT 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.